These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23634781)

  • 1. Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort.
    McWilliams DF; Kiely PD; Young A; Walsh DA
    BMC Musculoskelet Disord; 2013 May; 14():153. PubMed ID: 23634781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.
    Rantalaiho VM; Kautiainen H; Korpela M; Hannonen PJ; Leirisalo-Repo M; Möttönen T;
    Ann Rheum Dis; 2013 May; 72(5):786-8. PubMed ID: 23349132
    [No Abstract]   [Full Text] [Related]  

  • 9. Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.
    Bergstra SA; Allaart CF; Ramiro S; Chopra A; Govind N; Silva C; Murphy EA; Landewé RBM
    J Rheumatol; 2018 Oct; 45(10):1361-1366. PubMed ID: 29907672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
    Wojciechowski J; Wiese MD; Proudman SM; Foster DJ; Upton RN
    Br J Clin Pharmacol; 2015 May; 79(5):777-88. PubMed ID: 25394211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
    O'Dell JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
    de Jong PH; Hazes JM; Han HK; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; van Schaeybroeck B; de Sonnaville PB; van Krugten MV; Luime JJ; Weel AE
    Ann Rheum Dis; 2014 Jul; 73(7):1331-9. PubMed ID: 24788619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
    Proudman SM; James MJ; Spargo LD; Metcalf RG; Sullivan TR; Rischmueller M; Flabouris K; Wechalekar MD; Lee AT; Cleland LG
    Ann Rheum Dis; 2015 Jan; 74(1):89-95. PubMed ID: 24081439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
    Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
    Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
    O'Dell JR; Curtis JR; Mikuls TR; Cofield SS; Bridges SL; Ranganath VK; Moreland LW;
    Arthritis Rheum; 2013 Aug; 65(8):1985-94. PubMed ID: 23686414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
    Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
    Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
    Mittal N; Sharma A; Jose V; Mittal R; Wanchu A; Bambery P
    Rheumatol Int; 2012 Mar; 32(3):743-8. PubMed ID: 21161534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.